fda approved glp-1 receptor agonists Trends in the Development of GLP-1 Medications for Weight Loss:

Description

With production at existing sites running out of space to expand, a new site is being developed in northwestern Switzerland

[DOI] [PubMed] [Google Scholar] 186.Borah A.K., Ahmed S.A., Borah J.C

Finally, GLP-1 receptor agonists do not seem to affect negatively the cardiovascular risk in patients with T2D, but an ultimate all-clear regarding the risk of cardiovascular events, pancreatitis, or pancreatic cancer, which may be caused by incretin-mimetic drugs, cannot be given as there is scattered evidence for these side effects

Design In the obesity trial, 338 participants (mean age 48 years, 48% women, mean BMI 37.3 kg/m 2 ) were randomised (2:1:1:1:1:2:2) to retatrutide 1 mg, 4 mg (titration), 4 mg (no titration), 8 mg (slow titration), 8 mg (fast titration), 12 mg or placebo over 48 weeks [45]

Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats